The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of baseline characteristics on efficacy and safety after bortezomib-based induction and maintenance in newly diagnosed multiple myeloma (MM) patients ineligible for transplant in the phase IIIb UPFRONT study.
R. Niesvizky
Consultant or Advisory Role - Celgene; Millennium; Onyx
Research Funding - Celgene; Millennium; Onyx
I. W. Flinn
Research Funding - Millennium
R. M. Rifkin
Consultant or Advisory Role - Celgene; Millennium
Honoraria - Amgen; Celgene; Cephalon; Millennium
N. Gabrail
No relevant relationships to disclose
V. Charu
Stock Ownership - Amgen; Bristol-Myers Squibb; Pfizer
Honoraria - Amgen; Novartis
Research Funding - Amgen; Celgene; GlaxoSmithKline; Roche
Y. Gaffar
No relevant relationships to disclose
R. Neuwirth
Employment or Leadership Position - Millennium
D. Corzo
Employment or Leadership Position - Millennium
J. Reeves
No relevant relationships to disclose